$690,000 of SANOFI US SERVICES INC lobbying was just disclosed, from Q4 of 2024, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"Issues related to Pharmacy Benefit Managers (PBMs); issues related to Vaccines; issues related to Taxes; issues related to over the counter; and issues related to Insulin. Issues related to prescription-to- over the counter switch; issues related to influenza vaccines; issues related to 340B; issues related to Respiratory Syncytial Virus (RSV) access; general issues related to vaccines; issues related to clinical trial diversity; general issues related to drug pricing; issues related to out of pocket (OOP); general issues to insulin pricing; issues related to Additional Condition for Prescription Use (ACNU); issues related to copay accumulators; issues related to HR3656 "Vaccine Access Improvement Act"; issues related to Vaccine Issues Compensation Program (VICP); issues related to HR 830 "HELP Copays Act"; issues related to Pandemic and All-Hazards Preparedness Act (PAHPA)reauthorization; issues related to HR 1503 "Prescription Information Modernization Act of 2023"; general issues related FDA; issues related to FDA Drug Development; issues related to Pharmacy Benefit Managers (PBMs); issues related to insurance design; issues related to S. 1542 "DRUG Act"; issues related to S. 1375 "HELP Copays Act"; issues related to tax credits; issues related to S. 1339 "PBM Reform Act"; issues related to delinking; issues related to HR 2880 "Protecting Patients Against PBM Abuse Act"; issues related to Type 1 Diabetes screening; issues related to intellectual property; issues related to Transplant; issues related HR 5339 and S. 3131 "Orphan Cures Act"; Rare Pediatric Priority Review Voucher Program related to HR 7834 "Creating Hope Reauthorization Act of 2024"; Orphan Drug Negotiation within HR5378 "Inflation Reduction Act"; issues related to drug price negotiations; issues related to COPD Research funding; Biologic/Small Molecule drug negotiation eligibility within HR7174 "EPIC Act"; CDC Type 1 Diabetes Awareness and Education with LHHS appropriations; issues related to S.4504 "SCREEN for Type 1 Diabetes"; issues related to HRSA - Type 1 Diabetes Screening in LHHS Appropriations; general issues related to Inflation Reduction Act; issues related to Routine Immunizations Rates; issues related to HR5376 "Inflation Reduction Act"; issues related to Rebate Pass Through; and issues related to S. 2916 "Prescription Information Modernization Act of 2023"; Issues related to Medicare Negotiations; issues related to 340B; and issues related to Medicaid Drug Rebate Program rule. Issues related to Importation; and issues related to Supply Chain. General issues related to Taxes; issues related to Vaccine Injury Compensation Program (VICP); issues related to HR 3656 (117th) Vaccine Access Improvement Act; issues related to supply chain; and issues related to TRIP Waivers. Issues related to Intellectual Property."
You can find more data on corporate lobbying on Quiver Quantitative.
SNY Congressional Stock Trading
Members of Congress have traded $SNY stock 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $SNY stock by members of Congress over the last 6 months:
- REPRESENTATIVE JOHN JAMES sold up to $15,000 on 09/04.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
SNY Hedge Fund Activity
We have seen 366 institutional investors add shares of SNY stock to their portfolio, and 300 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FMR LLC removed 6,596,662 shares (-43.4%) from their portfolio in Q3 2024, for an estimated $380,165,631
- FRANKLIN RESOURCES INC added 5,946,912 shares (+197.5%) to their portfolio in Q3 2024, for an estimated $342,720,538
- PRICE T ROWE ASSOCIATES INC /MD/ added 3,890,678 shares (+209.0%) to their portfolio in Q3 2024, for an estimated $224,219,773
- MORGAN STANLEY added 3,041,391 shares (+20.6%) to their portfolio in Q3 2024, for an estimated $175,275,363
- BARROW HANLEY MEWHINNEY & STRAUSS LLC added 1,894,282 shares (+31.9%) to their portfolio in Q3 2024, for an estimated $109,167,471
- JENNISON ASSOCIATES LLC added 1,720,972 shares (+938.0%) to their portfolio in Q3 2024, for an estimated $99,179,616
- THRIVENT FINANCIAL FOR LUTHERANS added 1,424,289 shares (+28890.2%) to their portfolio in Q3 2024, for an estimated $82,081,775
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
